LGD-4033 (Ligandrol)

Receptor pharmacology

SARMs are studied for how they differ from classical androgens at the receptor level. Rather than simply activating the androgen receptor, non-steroidal ligands stabilise particular receptor conformations and recruit different coactivator and corepressor sets, and this is the mechanistic basis proposed for tissue selectivity. In-vitro work uses reporter assays, coregulator recruitment panels and receptor binding studies to place LGD-4033 relative to dihydrotestosterone and other reference ligands.

Analytical and anti-doping research

• LC-MS/MS methods for detecting parent compound and metabolites in urine and blood
• Metabolite identification work supporting long-detection-window assays
• Screening of consumer products, where independent analyses have repeatedly found mislabelled SARM content
• Reference-standard characterisation for laboratory quality control

Regulatory framing

No SARM has been approved for any indication. Regulators in the United States have taken action against products marketing SARMs as supplements, and anti-doping authorities prohibit them in and out of competition. Research with this material should be conducted under institutional oversight appropriate to an unapproved investigational compound.

Keep capsules in the original sealed bottle with any desiccant, at room temperature, away from heat, humidity and direct light. Store the liquid presentation upright in its amber bottle with the cap firmly closed; check for clarity before each use and note that solvent evaporation will concentrate the solution if the container is left open. Weigh or measure in a fume hood or ventilated enclosure, wear gloves and eye protection, and avoid generating dust when handling capsule contents. Label all working solutions with compound, concentration, solvent, lot and date, and dispose of surplus as chemical waste under your institutional procedures. Research use only.